68ga-nodaga-sna006
Small moleculeexperimentalImaging agent
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 2, 2021 (NCT05126927)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 68-gallium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07059832 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2024 | China Medical University |
| NCT05126927 | Early Phase 1 (Phase 1) | Nov 2, 2021 | SmartNuclide Biopharma, Soochow University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| China Medical University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| SmartNuclide Biopharma | For profit | 1 | 1 | 1 | 2021 |
| Soochow University | Academic/Hospital | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1